A 232 m², fully equipped BSL-3 research facility on the CNRS campus in Montpellier is available to academic and corporate scientists for studies involving BSL-3 agents.

CEMIPAI has over 350m² of Biosafety Level 2 and Biosafety Level 3 laboratory space (BSL-2 and BSL-3). These labs are fully equipped for in vitro viral and bacterias culture and assays. We also provide BSL-3 high-containment drug discovery services for evaluations of new therapeutics in the rapidly evolving fields of vaccines development, antiviral compounds, immunotherapy, gene therapy and cell therapy. Partnerships with Montpellier University’s animal biosafety lab (ABSL-3) form a full R&D pre-clinical value chain for efficacy studies.

Highly Experienced Personnel

In vitro studies conducted in our BSL-2 and BSL-3 facilities are directed by virologists and bacteriologists, with extensive experience in high-containment laboratories for research and select agent studies. Our technical staff is highly trained and experienced for conducting biosafety level 2 or 3 studies in infectious disease.

Full Suite of Supporting In Vitro Assays

Our in vitro assay support services are available for semi-automated drug screening against a growing number of viruses. We offer assay development, validation and performance verification. Learn more about our BSL-3 in vitro assays and virus production services

Unique BSL-3 imaging facilities

In addition to the research suites, our BSL-3 facility includes a shared instrument room. This space houses a photonic microscopy facility (Spinning Disk and TIRF video-microscopy for PALM/STORM super-resolution imaging), a high-speed Atomic Force Microscopy coupled with fluorescence microscopy and a videodrop for virus quantification and analysis.